- Details
- Mike Machaba Sathekge, MD, PhD presents on the power of medicine, specifically targeted radionuclide therapies and the use of actinium-225 in advanced prostate cancer. Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. He discusses the initial experience with 225Ac-PSMA-617 in a deve...
|
- Details
- Professor Michael Hofman presents details of a phase II prospective study on lutetium-PSMA-617. This study used the diagnostic companion of gallium-PSMA-11 to select patients with a high PSMA expression that were suitable for lutetium-PSMA-607 therapy. This was a prospective study. It was a 30 patient study and the results of that initial cohort were published in Lancet Oncology. This was followed...
|
- Details
- Maha Hussain highlights the pearls in the treatment landscape of metastatic hormone-sensitive, castration-resistant, and non-metastatic castration-resistant disease that came out of the last few years in prostate cancer in terms of the evolution of therapeutics. She details a plethora of clinical trials that had led to significant clinical benefit for patients, primarily overall survival advantage...
|
- Details
- In this 2019 LUGPA CME presentation by Neal Shore, he makes the case that now is the time to be developing your advanced bladder cancer clinics. There has been a tremendous amount of advancement in frontline metastatic bladder cancer and Neal Shore highlights some of the rapid changes in the field of both metastatic locally advanced and high-risk bladder cancer. PD receptor blockers, FGFR-targetin...
|
- Details
- In this presentation, Eric Rovner highlights the incontinence options for women and men, focusing primarily on mesh. Is mesh safe in men with stress incontinence? Is mesh safe for women? Why do some patients have complications with mesh? Are the surgeons to blame or is it the mesh itself? Dr. Rovner helps break down these questions in this LUGPA 2019 CME presentation. Biographies: Eric S. Rovner,...
|
- Details
- In urology, urinary tract infections are categorized into two main categories. Those with uncomplicated and those with complicated infections. Patients who have uncomplicated infections are young women premenopausal, not pregnant, and they have limited comorbidities. The symptoms that we associate with an uncomplicated infection are predominantly lower urinary tract urgency, dysuria, blood in the...
|
- Details
- Brian Helfand presents the use of genomics today to personalize the treatment of men with prostate cancer and the different models on how to implement this testing in your clinic. There are not enough genetic counselors throughout the country to answer everyone's needs, so it is important as a urologist to start initiating these conversations with patients. Biographies: Brian T. Helfand, M.D., Ph....
|
- Details
- Daniel Spratt presents on practical aspects of the technological evolution in radiation therapy during the 2019 LUGPA CME session. He focuses his presentation on technological advances in radiation therapy including a hybrid of software and hardware, which is the technology of our ability to plan radiation therapy going from a 2D to 3D to IMRT era, imaging tumors when you put a patient on a machin...
|
- Details
- Alan Wolfe disputes the old dogma that the bladder is sterile. He explains that there are bacteria that normally live in healthy bladders called the urinary microbiota or urinary microbiome and gets into much more detail in this 2019 LUGPA CME presentation. Biography: Alan J. Wolfe, PhD, Department of Microbiology and Immunology, Loyola University Chicago, Chicago, Illinois, USA. Related Content:...
|
- Details
- Daniel Watson and Alan Burns present their collaborative approach in favor of percutaneous renal mass cryoablation for renal masses. To date, Dr. Watson and Burns have done 207 of these procedures. The mean age of the patient is approximately 69 years and the mean size of the lesions is about 2.3 centimeters. Dr. Watson suggests a 85% cure rate with this procedure. Biographies: Daniel L. Watson, M...
|
